Use: Labeled indications
- INDICATIONS AND USAGE OCUFLOX ® ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive…
Full indications and usage US FDA label
INDICATIONS AND USAGE OCUFLOX ® ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections
Contraindications
CONTRAINDICATIONS OCUFLOX ® solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (s ee Warnings).
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION The recommended dosage regimen for the treatment of bacterial conjunctivitis is: Days 1 and 2 Instill one to two drops every two to four hours in the affected eye(s). Days 3 through 7 Instill one to two drops four times daily. The recommended dosage regimen for the treatment of bacterial corneal ulcer is: Days 1 and 2 Instill one to two drops into the affected eye every 30 minutes, while awake.
Awaken at approximately four and six hours after retiring and instill one to two drops. Days 3 through 7 to 9 Instill one to two drops hourly, while awake. Days 7 to 9 through treatment completion Instill one to two drops, four times daily.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Safety and effectiveness in infants below the age of one year have not been established. Quinolones, including ofloxacin, have been shown to cause arthropathy in immature animals after oral administration; however, topical ocular administration of ofloxacin to immature animals has not shown any arthropathy. There is no evidence that the ophthalmic dosage form of ofloxacin has any effect on weight bearing joints.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Dosage forms
Philippines
- Ophthalmic solution: 3 mg/mL
- Otic solution: 3 mg/mL
- Tablet: 200 mg, 400 mg
- Film-coated tablet: 200 mg, 400 mg
- ) solution for i.v. infusion: 2 mg/mL (200 mg/100 mL, 200 MG/100 ML (2 MG/ML
- ) solution for intravenous infusion: 2 mg/mL (200 mg/100 mL
- ) solution for iv infusion: 2 mg/mL (200 mg/100 mL, 200 mg/100 mL (2 mg/mL
- Capsule: 200 mg
- ) solution for infusion: 200 mg/100 mL (2 mg/mL
- Eye drops solution: 3 mg/mL
and 6 more forms; see the products table.
Registered products in the Philippines
56 products registered with the Food and Drug Administration (FDA) Philippines list Ofloxacin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products56
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AflacinOfloxacin | 3 mg/mL (0.3% w/v) Sterile Ophthalmic Solution (Eye Drops)Sterile LDPE dropper tip bottle x 5 mL (Box of 1's) | Rx | Laboratorios Ashford Lda.China | Marrion Pharma Inc. | DRP-6033 | Feb 15, 2037 | |
Agua OfioOfloxacin | 3 mg/mL (0.3% w/w) Ophthalmic SolutionOpaque Plastic Bottle x 5mL and 10 mL (Box of 1's) | Rx | Indiana OphthalmicsIndia | Agua Visions TradingImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4998-01 | Sep 7, 2027 | |
AkuofloOfloxacin | 2 mg/mL Solution for I.V. InfusionLDPE Plastic Bottle with White Plastic Cap x 100 mL (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-4291 | Mar 8, 2037 | |
DizofloxOfloxacin | 3 mg/mL (0.3%) Ophthalmic Solution (Eye Drops)5 mL in 10mL E/D Plastic filled with a whole plastic dropper plug with white plastic tamper proof cap (Box of 1's) | Rx | Ashford Pharamceutical Laboratories, Inc.Philippines | Trader: Vendiz Pharmaceuticals, Inc. | DRP-10387 | Jan 6, 2031 | |
DizofloxOfloxacin | 3 mg/mL (0.3%) Otic Solution10 mL LDPE Plastic Bottle 5 mL content and 2.5 mL Physician Sample (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Vendiz Pharmaceuticals Inc. | DRP-10526 | Feb 18, 2029 | |
ElifloxOfloxacin | 200mg CapsuleFoil Strip x 10's Box of 100's | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5602 | May 26, 2027 | |
FamoxaOfloxacin | 200mg / 100mL (2mg / mL) Solution for IV InfusionPolypropylene (PP) Bottle x 100 mL (Box of 1's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Importer: AMB HK Enterprises Inc. | DRP-11321 | Feb 28, 2032 | |
FloaxaOfloxacin | 3mg/mL (0.3%w/v) Ophthalmic Solution10 mL LDPE vial with spike cap (Box of 1's) | Rx | Axa Parenterals LimitedIndia | Brady Pharma Inc. | DRP-11946 | May 23, 2027 | |
FloxOfloxacin | 2 mg/mL (200 mg/100 mL) Solution for I.V. InfusionLDPE bottle x 100 mL (Box of 1's) | Rx | Amanta Healthcare Ltd.India | Endure Medical, Inc. | DR-XY36667 | Sep 17, 2029 | |
Floxa-200Ofloxacin | 200 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Remedies Pvt. Ltd.India | Importer: Philgen Pharmaceuticals Inc. | DRP-2505 | Oct 8, 2030 | |
Floxa-400Ofloxacin | 400 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Remedies Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-2506 | Oct 8, 2030 | |
FloxacincareOfloxacin | 3 mg / mL (0.3% w/w) Ophthalmic SolutionOpaque Plastic Bottle x 5mL and 10 mL (Box of 1's) | Rx | Indiana OphthalmicsIndia | Sensorycare Pharma Co.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4998-02 | Sep 7, 2027 | |
FloxagenOfloxacin | 200 mg TabletAluminum Foil Strip x 10's (Box of 100's) | Rx | Sydenham Laboratories, Inc.Philippines | Trader: Vonnace Pharmaceuticals Corporation | DR-XY20695-B | May 30, 2027 | |
FloxopOfloxacin | 0.3% w/v Ophthalmic Solution5 mL Sterile Solution Filled in 5 mL Milky White LDPE Vial (Box of 1's) | Rx | East African (India) OverseasIndia | Airlife International Trading Corp. | DRP-17899 | Apr 7, 2031 | |
Floxy-200Ofloxacin | 200 mg TabletFoil Strip x 10's (Box of 100's) | Rx | Millimed Co., LTD.Thailand | MG Prime Pharmaceutical, Inc.Importer: Atlantic Pharmaceuticals Inc. | DRP-2589 | Aug 25, 2031 | |
FluraxidOfloxacin | 200 mg Film-Coated TabletFoil Strip x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals, Phils., Inc. | DR-XY30380 | Dec 10, 2029 | |
FluraxidOfloxacin | 400 mg Film-Coated TabletFoil Strip x 10's Box of 50's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals, Phils., Inc. | DR-XY30379 | Dec 10, 2029 | |
FolaxinOfloxacin | 200 mg Film-Coated TabletFoil Strip x 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Euro-Health Care Exponents, Inc. | DRP-6835-01 | Jan 13, 2030 | |
IblesOfloxacin | 3 mg/mL (0.3% w/v) Ophthalmic SolutionOpaque White Plastic Dropper Container with Nozzle and Cap x 5 mL (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Importer: Afree Pharmaceutical Distribution Corp. | DRP-12653 | Sep 19, 2027 | |
InofloxOfloxacin | 200 mg TabletAluminum Flex Foil x 6's (Box of 30's); Aluminum Flex Foil x 4's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY7575 | May 24, 2031 | |
InofloxOfloxacin (as hydrochloride) | 200 mg/100 mL Solution for Infusion (IV)100 mL Clear and colorless glass vial with rubber stopper and green flip-off seal (Box of 1's) | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY28272 | Jan 30, 2028 | |
InofloxOfloxacin | 3 mg/mL Otic SolutionSqueezable Plastic Container x 5 mL (Box of 1's) | Rx | Santen Pharmaceuticals Co., Ltd. (Noto Plant)Japan | UNILAB, Inc. | DR-XY21447 | Jun 7, 2027 | |
InofloxOfloxacin | 400 mg TabletAluminum Flex Foil x 10's (Box of 30's); Aluminum Flex Foil x 4's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY18641 | May 24, 2031 | |
LofectionOfloxacin | 400 mg TabletBlister Pack x 6's in individual box (Box of 60's) | Rx | Unichem Laboratories LimitedIndia | Ambica International Corporation | DRP-6464 | Jul 15, 2032 | |
NoneOfloxacin | 200mg CapsuleFoil Strip x 10's Box of 100's | Rx | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-5602-01 | May 26, 2027 | |
NoneOfloxacin | 3 mg/mL (0.3% w/v) Ophthalmic SolutionPlastic squeeze bottle x 5 mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Celsus Pharmaceuticals Phils., Inc.Trader: Pharmabiz Solutions, Inc. | DRP-2449-01 | Mar 16, 2031 | |
NoneOfloxacin | 3 mg/mL (0.3% w/v) Otic SolutionPlastic Bottle x 5 mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Celsus Pharmaceuticals Phils., Inc.Trader: Pharmabiz Solutions, Inc. | DRP-2448-01 | Mar 6, 2031 | |
OcinOfloxacin | 3 mg/mL (0.3% w/v) Eye Drops SolutionLow Density Polyethylene (LDPE) FFS Container x 5 mL | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DR-XY36568 | Aug 27, 2031 | |
OfiyanaOfloxacin | 3 mg/mL (0.3% w/v) Ophthalmic Solution10 mL opaque plastic bottle with white opaque LDPE nozzle and white opaque HDPE cap (Box of 1's) | Rx | Indiana OphthalmicsIndia | Aglobal Care, Inc. | DRP-13691 | Apr 13, 2028 | |
OflazOfloxacin | 3 mg / mL (0.3% w/v) Ophthalmic Solution15 mL White LDPE Bottle Sealed with Cap x 10 mL (Net content) (Box of 1’s) | Rx | Skymap Healthcare Pvt. Ltd.India | Ophtha Pharma Traders Inc.Importer: AMB HK Enterprises, Inc. | DRP-11588-02 | Mar 30, 2027 | |
OflobizOfloxacin | 3 mg/mL (0.3% w/v) Ophthalmic SolutionPlastic Squeeze Bottle x 5 mL Box of 1's | Rx | ASHFORD PHARMACEUTICAL LABORATORIES, INC.Philippines | Trader: PHARMABIZ SOLUTIONS, INC. | DRP-2449 | Feb 15, 2037 | |
OflobizOfloxacin | 3 mg/mL (0.3% w/v) Otic SolutionPlastic bottle x 5 mL Box of 1's | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Pharmabiz Solutions, Inc. | DRP-2448 | Feb 9, 2037 | |
OFLOLIFEOFLOXACIN | 200 MG/ 100 ML (2 MG/ML) Solution For I.V. InfusionLDPE Blow Molded Bottle x 100 mL (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Aglobal Care, Inc. | DRP-7922 | Nov 8, 2031 | |
OflomaxOfloxacin | 2mg/mL (200mg/100mL) Solution for IV InfusionType I Clear Glass Bottle x 100mL (Box of 1's) | Rx | Lu'an Worldbest Pharmaceutical Co., Ltd.China | Global Pharmatrade | DR-XY41410 | Nov 13, 2027 | |
OflotechOfloxacin | 2 mg/mL (0.2 % w/v) Solution for IV Infusion100 mL LDPE Plastic Bottle (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3939 | Sep 5, 2030 | |
Ofloxasaph-INFOfloxacin | 2 mg/mL (200 mg/100 mL) Solution for Intravenous Infusion100 mL LDPE bottle with white protective cap (Box of 1's) | Rx | Althea Pharma Pvt. Ltd.India | Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt., Ltd. | DRP-15072 | Apr 12, 2029 | |
Ofloxasaph-INFOfloxacin | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops)5 mL white HDPE dropper bottle with plastic nozzle and plastic cap (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-14880 | Jan 31, 2029 | |
Ofloxasaph-OtOfloxacin | 2 mg/mL (200 mg/100 mL) Solution For I.V. InfusionWhite colored LDPE Bottle x 100 mL (Box of 1's) | Rx | Althea Pharma Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13320 | Jan 26, 2028 | |
OfloxasaveOfloxacin | 3 mg/mL Ophthalmic Solution (Eye Drops)White HDPE Plastic Bottle x 5 mL (Box of 1's) | Rx | Opal Laboratories (Pvt.) LimitedPakistan | Savelink Pharma and Trading Co.Importer: Accesspoint International Trading Inc. | DRP-13789-01 | Apr 20, 2028 | |
OfloxenOfloxacin | 3 mg/g (0.3% w/w) Ophthalmic Ointment2 g Aluminum Collapsible Tube (Box of 1's) | Rx | Cisen Pharmaceutical Co., LtdChina | Endure Medical Inc. | DR-XY43502 | Jun 25, 2029 | |
OframacOfloxacin | 200 mg Film-Coated TabletFoil Strip x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-6835 | Jan 13, 2030 | |
OframacOfloxacin | 400 mg Film-Coated TabletStrip Foil x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-9421 | Jan 18, 2031 | |
OleOfloxacin | 3 mg/mL (0.3% w/w) Ophthalmic SolutionOpaque Plastic Bottle x 5mL and 10 mL (Box of 1's) | Rx | Indiana OphthalmicsIndia | Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4998 | Sep 7, 2027 | |
OmefloxOfloxacin | 3 mg/mL (0.3% w/v) Otic SolutionLDPE Bottle x 5 mL (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Ensight Pharmaceuticals Inc.Trader: Entod Pharmaceuticals Ltd. | DR-XY49759 | Jul 6, 2031 | |
OplaseOfloxacin | 3mg/mL (0.3% w/v) Ophthalmic Solution15 mL White LDPE Bottle Sealed with Cap x 10 mL (Net content) (Box of 1's) | Rx | Skymap Healthcare Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-11588 | Mar 30, 2027 | |
OplaseOfloxacin | 3mg/mL (0.3% w/v) Ophthalmic Solution15 mL White LDPE Bottle Sealed with Cap x 10 mL (Net content) (Box of 1's) | Rx | Skymap Healthcare Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-11839 | May 6, 2027 | |
OptiquinOfloxacin | 3 mg/mL Ophthalmic Solution (Eye Drops)White HDPE Plastic Bottle x 5 mL (Box of 1's) | Rx | Opal Laboratories (Pvt.) Limited.Pakistan | Accesspoint International Trading, Inc. | DRP-13789 | Apr 20, 2028 | |
OtofloxOfloxacin | 3 mg/mL (0.3% w/v) Otic Solution (Drops)HDPE Plastic Bottle x 7.5 mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Sensomed Phils., Inc. | DR-XY32631 | Nov 17, 2031 | |
OttofloxOfloxacin | 3 mg/mL Otic SolutionIn opaque white LDPE bottle with transparent dropper insert and opaque white HDPE cap with tamper-proof closure x 10 mL (Box of 1's) | Rx | Laboratorio Edol - Produtos Farmaceuticos, S.A.Portugal | Ambicare Pharmaceuticals Inc. | DRP-9349 | Feb 9, 2037 | |
QinolonOfloxacin | 200 mg TabletFoil Strip Pack x 4's Box of 100's | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DR-XY7167 | May 25, 2027 | |
QinolonOfloxacin (as hydrochloride) | 200 mg/100 mL (2 mg/mL) Solution for Infusion (IV)100 mL Clear glass vial with rubber stopper and green flip-off seal (Box of 1's) | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY28270 | Jan 30, 2028 | |
QinolonOfloxacin | 400 mg TabletAluminum Flex Foil x 4's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY18554 | Aug 2, 2027 | |
QuinoCareOfloxacin | 3 mg/mL (0.3% w/v) Otic SolutionPlastic bottle x 5 mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Rizal | Sensorycare Pharma Co.Trader: Pharmabiz Solutions, Inc. | DRP-2448-02 | May 14, 2030 | |
SiofloxOfloxacin | 2 mg/mL (200 mg/ 100 mL) Solution for Intravenous Infusion100 mL in white transparent Low Density Polyethylene (LDPE) bottle with euro-head plastic cap (Box of 1's) | Rx | Albert David LimitedIndia | Medethix, Inc. | DRP-6905 | Nov 3, 2029 | |
UnbrandedOfloxacin | 400 mg TabletFoil Strip x 10's (Box of 100's) | Rx | Pascual Laboratories, Inc.Bulacan | Pharex Health Corporation | DRP-5937 | Dec 6, 2031 | |
ZOOFLOXACIN | 3 mg/mL (0.3% w/v) Ophthalmic SolutionLow Density Polyethylene (LDPE) Plastic Vial x 5 mL Box of 1's | Rx | FDC LIMITEDIndia | PENTA LABS AUSTRALIA (PHILIPPINES) | DRP-5570 | Dec 5, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS NOT FOR INJECTION. OCUFLOX ® solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye. There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin.
Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin.
If an allergic reaction to ofloxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management, including intubation should be administered as clinically indicated.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions Specific drug interaction studies have not been conducted with OCUFLOX ® ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Ophthalmic Use The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort. Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain. Rare reports of dizziness and nausea have been received. Refer to Warnings for additional adverse reactions.
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic Effects Ofloxacin has been shown to have an embryocidal effect in rats and in rabbits when given in doses of 810 mg/kg/day (equivalent to 9000 times the maximum recommended daily ophthalmic dose) and 160 mg/kg/day (equivalent to 1800 times the maximum recommended daily ophthalmic dose). These dosages resulted in decreased fetal body weight and increased fetal mortality in rats and rabbits, respectively.
Minor fetal skeletal variations were reported in rats receiving doses of 810 mg/kg/day. Ofloxacin has not been shown to be teratogenic at doses as high as 810 mg/kg/day and 160 mg/kg/day when administered to pregnant rats and rabbits, respectively.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers In nursing women a single 200 mg oral dose resulted in concentrations of ofloxacin in milk which were similar to those found in plasma. It is not known whether ofloxacin is excreted in human milk following topical ophthalmic administration. Because of the potential for serious adverse reactions from ofloxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pharmacokinetics
Ofloxacin was excreted in the urine primarily unmodified.
Pharmacokinetics (US label) US FDA label
Pharmacokinetics Serum, urine and tear concentrations of ofloxacin were measured in 30 healthy women at various time points during a ten-day course of treatment with OCUFLOX ® solution. The mean serum ofloxacin concentration ranged from 0.4 ng/mL to 1.9 ng/mL. Maximum ofloxacin concentration increased from 1.1 ng/mL on day one to 1.9 ng/mL on day 11 after QID dosing for 10 1/2 days.
Maximum serum ofloxacin concentrations after ten days of topical ophthalmic dosing were more than 1000 times lower than those reported after standard oral doses of ofloxacin. Tear ofloxacin concentrations ranged from 5.7 to 31 mcg/g during the 40 minute period following the last dose on day 11. Mean tear concentration measured four hours after topical ophthalmic dosing was 9.2 mcg/g.
Corneal tissue concentrations of 4.4 mcg/mL were observed four hours after beginning topical ocular application of two drops of OCUFLOX ® ophthalmic solution every 30 minutes. Ofloxacin was excreted in the urine primarily unmodified.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Ofloxacin Ear Drops 0.3%, 5 mL Bottle | ₱175.00–₱250.00Reference ₱200.00 | per bottle | DPRI procurement range |
| Ofloxacin Eye Drops 0.3%, 5 mL Bottle | ₱167.00–₱170.00Reference ₱167.00 | per bottle | DPRI procurement range |
| Ofloxacin 200 mg Tablet | ₱1.78–₱4.85Reference ₱3.75 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Ofloxacin |
| PNF listing | Oral: 200 mg tablet |
| PNF listing | Eye Drops Solution: 0.3%, 5 mL bottle |
| PNF listing | Ear Drops Solution: 0.3%, 5 mL bottle |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. OCUFLOX · Allergan, Inc. [US FDA-approved label, version 13, June 13, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7aab4449-3dda-4e2c-8e40-b3244a548bf5
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .